Patent ductus arteriosus (PDA) is the common complication in prematurity. Intravenous indomethacin three doses is the effective medication for closure PDA but the complication about renal impairment and gastrointestinal(GI) problem should be aware. Low dose Indomethacin, patent ductus arteriosus, preterm
Conditions
Interventions
Group 1 64 patients who received 2 doses of IV indomethacin (0.2 mg/kg/dose) , Group 2 64 patients who received 3 doses of IV indomethacin (0.2 mg/kg/dose)
Experimental Drug,Experimental Drug
Indomethacin Low dose,Indomethacin Normal dose
Sponsors
Chonburi hospital
Eligibility
Sex/Gender
All
Age
1 Days to 6 Days
Inclusion criteria
Inclusion criteria: 1.Preterm newborn less than 34 weeks or body weight less than 1,500 grams with age less than 6 days who had hemodynamically significant PDA (PDA size more than or equal 1.5 mm and the presence of reversal flow in the descending aorta or a Left Atrium: Aorta ratio 1.4:1 by echocardiogram)
Exclusion criteria
Exclusion criteria: 1.Major congenital anomalies such as cyanotic heart disease , Genetic disease 2.Abnormal renal anatomy 3.Life threatening sepsis 4.Necrotizing enterocolitis 5.Intraventricular hemorrhage 6.Creatinine > 1.5 mg/dL 7. platelet count < 100,000 /ml
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success closure rate of PDA at 72 hours and 7 days after closure PDA Report of echocardiogram | — |
Secondary
| Measure | Time frame |
|---|---|
| Repeat treatment -NEC, GI bleeding, Renal impairment 72 hours and 7 days after closure PDA Number of patients | — |
Countries
Thailand
Contacts
Public ContactWasana Hongkan
Chonburi hospital
Outcome results
None listed